Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations

It has become clear that rituximab treatment is useful for both B-cell malignancies and autoimmune rheumatic diseases. However this treatment is associated with an increased risk of an allergic reaction. We have reviewed the frequency with which these reactions occur in these different conditions. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilaberte Reyzabal, Sergio, Isenberg, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149152/
https://www.ncbi.nlm.nih.gov/pubmed/35652065
http://dx.doi.org/10.3389/fmed.2022.882891
_version_ 1784717143226449920
author Gilaberte Reyzabal, Sergio
Isenberg, David
author_facet Gilaberte Reyzabal, Sergio
Isenberg, David
author_sort Gilaberte Reyzabal, Sergio
collection PubMed
description It has become clear that rituximab treatment is useful for both B-cell malignancies and autoimmune rheumatic diseases. However this treatment is associated with an increased risk of an allergic reaction. We have reviewed the frequency with which these reactions occur in these different conditions. They appear to be less frequent when rituximab is used to treat rheumatoid arthritis and systemic lupus perhaps because concomitant steroids are invariably given to these patients with the rituximab which is not necessarily the case with the treatment of B-cell malignancies.
format Online
Article
Text
id pubmed-9149152
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91491522022-05-31 Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations Gilaberte Reyzabal, Sergio Isenberg, David Front Med (Lausanne) Medicine It has become clear that rituximab treatment is useful for both B-cell malignancies and autoimmune rheumatic diseases. However this treatment is associated with an increased risk of an allergic reaction. We have reviewed the frequency with which these reactions occur in these different conditions. They appear to be less frequent when rituximab is used to treat rheumatoid arthritis and systemic lupus perhaps because concomitant steroids are invariably given to these patients with the rituximab which is not necessarily the case with the treatment of B-cell malignancies. Frontiers Media S.A. 2022-05-16 /pmc/articles/PMC9149152/ /pubmed/35652065 http://dx.doi.org/10.3389/fmed.2022.882891 Text en Copyright © 2022 Gilaberte Reyzabal and Isenberg. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Gilaberte Reyzabal, Sergio
Isenberg, David
Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
title Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
title_full Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
title_fullStr Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
title_full_unstemmed Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
title_short Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
title_sort differences in the development of adverse infusion reactions to rituximab in patients with systemic lupus erythematosus, rheumatoid arthritis and non-hodgkin's lymphoma-enigma variations
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149152/
https://www.ncbi.nlm.nih.gov/pubmed/35652065
http://dx.doi.org/10.3389/fmed.2022.882891
work_keys_str_mv AT gilabertereyzabalsergio differencesinthedevelopmentofadverseinfusionreactionstorituximabinpatientswithsystemiclupuserythematosusrheumatoidarthritisandnonhodgkinslymphomaenigmavariations
AT isenbergdavid differencesinthedevelopmentofadverseinfusionreactionstorituximabinpatientswithsystemiclupuserythematosusrheumatoidarthritisandnonhodgkinslymphomaenigmavariations

Ejemplares similares